Last update 08 May 2025

Supi Pharmaceutical (Guangzhou) Co., Ltd.

Dissolved
| Private Company|2019|Guangdong Sheng, China|
www.sobi.com

Overview

Tags

Congenital Disorders
Immune System Diseases
Hemic and Lymphatic Diseases
Monoclonal antibody

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Neoplasms1
Immune System Diseases1
Hemic and Lymphatic Diseases1
Top 5 Drug TypeCount
Monoclonal antibody1
Top 5 TargetCount
IFNγ(Interferon gamma)1

Related

2
Drugs associated with Supi Pharmaceutical (Guangzhou) Co., Ltd.
Emapalumab-LZSG
Target
IFNγ
Mechanism
IFNγ inhibitors
Active Org.
Swedish Orphan Biovitrum ABSwedish Orphan Biovitrum AB [+3]
Originator Org.
NovImmune SANovImmune SA
Active Indication
Lymphohistiocytosis, Hemophagocytic [+15]
Inactive Indication
COVID-19 [+3]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
United States
First Approval Date20 Nov 2018
SEL-212
Target
Uric acid
Mechanism
Uric acid modulators
Active Org.
Swedish Orphan Biovitrum ABSwedish Orphan Biovitrum AB
Originator Org.
Selecta Biosciences, Inc.Selecta Biosciences, Inc.
Active Indication
Chronic tophaceous gout
Inactive Indication
Hyperuricemia
Drug Highest PhaseNDA/BLA
First Approval Ctry. / Loc.-
First Approval Date-
2
Clinical Trials associated with Supi Pharmaceutical (Guangzhou) Co., Ltd.
CTR20232771
/ Not yet recruitingNot Applicable
一项描述中国遗传性酪氨酸血症Ⅰ型（HT-1）患者在常规临床诊疗中接受Nitisinone治疗后结局的前瞻性、非干预性、上市后研究
[Translation] A prospective, non-interventional, post-marketing study describing the outcomes of Chinese patients with hereditary tyrosinemia type 1 (HT-1) treated with nitisinone in routine clinical care
CTR20222253
/ Active, not recruitingPhase 4
一项描述依马利尤单抗用于治疗原发性噬血细胞性淋巴组织细胞增多症中国经治患者的安全性和有效性的开放性、单臂、多中心、上市后研究
[Translation] An open-label, single-arm, multicenter, post-marketing study to describe the safety and efficacy of imalimumab in Chinese patients with previously treated primary hemophagocytic lymphohistiocytosis
100 Clinical Results associated with Supi Pharmaceutical (Guangzhou) Co., Ltd.
Login to view more data
0 Patents (Medical) associated with Supi Pharmaceutical (Guangzhou) Co., Ltd.
Login to view more data
100 Deals associated with Supi Pharmaceutical (Guangzhou) Co., Ltd.
Login to view more data
100 Translational Medicine associated with Supi Pharmaceutical (Guangzhou) Co., Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 10 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Phase 3 Clinical
1
1
Other
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Emapalumab-LZSG
 ( IFNγ )		Polyarticular Juvenile Idiopathic Arthritis
More
Phase 3 Clinical
SEL-212
 ( Uric acid )		Gout
More
Pending
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free